Stefania Bartolini

A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.

G. Scagliotti, F. Cappuzzo, S. Novello, 2006, Lung cancer.

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

M. Dieci, D. Generali, A. Prat, 2023, Journal of the National Cancer Institute.

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

N. Biglia, A. Brandes, A. Musolino, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

G. Scagliotti, A. Ceribelli, S. Novello, 2005, British Journal of Cancer.

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

F. Cappuzzo, F. Hirsch, P. Bunn, 2005, British Journal of Cancer.